This milestone represents significant progress in Ferring’s manufacturing capabilities to meet anticipated growth in demand for Adstiladrin® (nadofaragene firadenovec-vncg), a gene therapy for people with non-muscle invasive bladder cancer (NMIBC). With bladder cancer now the ninth most…

OPTIMISE study found a treat-to-target (T2T) management strategy in people with mild-to-moderate ulcerative colitis (M2M UC) being treated with 5-aminosalicylic acid (5-ASA; mesalazine) utilising faecal calprotectin (FC) home monitoring over 12 months achieved…

Ferring appoints Dr Michael Rosenblatt to its Board of Directors. Dr Rosenblatt has served as a founding scientist, scientific advisory board member, and director of several biopharmaceutical companies. Jan Lundberg is stepping down from his role of Chairman of…